Clinical Trials Directory

Trials / Completed

CompletedNCT00949780

Chloral Hydrate to Perform Auditory Brainstem Response (ABR)

Use of Chloral Hydrate to Perform Auditory Brainstem Response (ABR)

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
41 (actual)
Sponsor
Pontificia Universidade Catolica de Sao Paulo · Academic / Other
Sex
All
Age
1 Year – 11 Years
Healthy volunteers
Not accepted

Summary

Chloral Hydrate (CH) is a well known drug for sedative and hypnotic purposes used in pediatric and dental procedures owing to the low depressive effect it has over respiratory and cardiac systems. Despite that, the literature reports cases of heart arrhythmia and sudden death in children, especially when using high doses, probably due to accumulation of serum trichloroethanol, an intermediate metabolite resulting from the liver metabolism of the drug. A possible carcinogenic action observed in guinea pigs has also been reported, even though it has not been confirmed in human beings. Among the least severe complications there are paradoxical agitation, nausea, vomiting and excessive sleepiness. CH is the drug of choice to sedate children undergoing Auditory Brainstem Response test (ABR), in which any movement or muscle contraction may generate artifacts that interfere in the analysis. Profound sleep that lasts on average one hour is rapidly induced depending on the used dose, causing no residual sleepiness after this period; however, there is consensus in the literature about the best dose, which may range from 40 to 100 mg/kg. Objective: To assess the efficacy of CH as a sedative agent in performing ABR in children and to systematize its use.

Conditions

Interventions

TypeNameDescription
DRUGChloral Hydrate

Timeline

Start date
2007-10-01
Primary completion
2008-03-01
Completion
2008-10-01
First posted
2009-07-30
Last updated
2009-07-31

Locations

2 sites across 1 country: Brazil

Source: ClinicalTrials.gov record NCT00949780. Inclusion in this directory is not an endorsement.